See the DrugPatentWatch profile for cosentyx

There is currently no definitive scientific research or studies indicating that Cosentyx (secukinumab) directly affects the effectiveness of inactivated vaccines. Cosentyx is a biologic medication used to treat various autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by inhibiting the activity of interleukin-17A, a protein involved in inflammation [1].

However, patients taking Cosentyx or other immunosuppressive drugs might experience altered responses to vaccines, including reduced efficacy and increased risk of adverse reactions [2]. The Centers for Disease Control and Prevention (CDC) recommends that individuals on immunosuppressive therapy, like Cosentyx, consult their healthcare providers to discuss the need for vaccination and the optimal timing for administering vaccines [2].

In summary, while there is no evidence suggesting that Cosentyx directly impacts the effectiveness of inactivated vaccines, patients taking Cosentyx should consult their healthcare providers regarding vaccinations due to their potentially weakened immune systems [1, 2].

Sources:
[1] Drugs.com. Cosentyx. <https://www.drugs.com/cosentyx.html>
[2] Centers for Disease Control and Prevention. Vaccination of Persons with Weakened Immune Systems. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer-biontech.html#vaccination-of-persons-with-weakened-immune-systems>